Abstract:Classical swine fever virus (CSFV) is the etiological agent of classical swine fever, a highly contagious dis-ease that causes significant economic losses to the swine industry. Systemic prophylactic immunization with the live attenuated vaccine, the C-strain vaccine, is one of the effective measures for CSF control. However, one of the limitations of the C-strain vaccine is that the field strains-infected animals cannot be differentiated from the C-strain vaccinated herds by serological tests (DIVA). This constraint hampers the practical usage of the C-strain vaccine to eradicate the CSF in China. In the current study, a novel CSF modified live marker vaccine candidate was constructed based on the attenuation of the prevalent 2.1 genotype strain by the deletion of two virulence associated functional residues in the CSFV Erns, H79, and C171. Meanwhile, four residues S14, G22, E24, and E25 were identified specifically for the 6B8 mAb binding to the CSFV E2 as the novel conformational epitope. Then four substitutions of S14K, G22A, E24R, and G25D were further incorporated in the double deletion construct as a negative serolog-ical marker. Finally, the double-deletion marker MLV candidate GD18-ddErnHC-KARD was rescued, and its safety and efficacy profiles were evaluated in piglets. The safety study results indicated that the can-didate did not induce fever, clinical signs, or pathological lesions with a high dose of 105.0 TCID50, and in addition, no virus shedding was detected until 21 days post-inoculation. Meanwhile, the efficacy study results demonstrated that at a low dose of 103.0 TCID50, it conferred complete clinical protection and no virus shedding was detected after the challenge with a highly virulent Shimen strain. Importantly, the infected animals were differentiated using the accompanied DIVA ELISA. These results constitute a proof-of-concept for rationally designing a CSF antigenically marked modified live vaccine candidate.(c) 2022 Elsevier Ltd. All rights reserved.

Candidate Multi-Peptide-Vaccine Against Classical Swine Fever Virus Induces Strong Antibody Response with Predefined Specificity

Candidate Peptide Vaccine Induced Protection Against Classical Swine Fever Virus

Candidate Peptide-Vaccine Induced Potent Protection Against Csfv and Identified A Principal Sequential Neutralizing Determinant on E2

Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2.

Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker.

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Candidate Vaccine Focused on a Classical Swine Fever Virus Epitope Induced Antibodies with Neutralizing Activity.

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Construction of a Chimeric Classical Swine Fever Virus C-strain Containing E2 of Group Ⅱ Isolate Remains and Its Biological Characteristics

The Protective Immune Response Induced by B Cell Epitope of Classical Swine Fever Virus Glycoprotein E2

Preliminary Evaluation of a Candidate Multi-Epitope-Vaccine Against the Classical Swine Fever Virus

Multiple Linear B-cell Epitopes of Classical Swine Fever Virus Glycoprotein E2 Expressed in E.coli As Multiple Epitope Vaccine Induces a Protective Immune Response

Glycoprotein E2 of Classical Swine Fever Virus Expressed by Baculovirus Induces the Protective Immune Responses in Rabbits

Efficient Mucosal Vaccination of a Novel Classical Swine Fever Virus E2-Fc Fusion Protein Mediated by Neonatal Fc Receptor.

Hypervariable Antigenic Region 1 of Classical Swine Fever Virus E2 Protein Impacts Antibody Neutralization.

Chimeric Epitope Vaccine Against Leptospira Interrogans Infection and Induced Specific Immunity in Guinea Pigs

Generation and Efficacy Evaluation of Recombinant Classical Swine Fever Virus E2 Glycoprotein Expressed in Stable Transgenic Mammalian Cell Line

Poly(I:C) Combined with Multi-Epitope Protein Vaccine Completely Protects Against Virulent Foot-and-mouth Disease Virus Challenge in Pigs

A Promising Trigene Recombinant Human Adenovirus Vaccine Against Classical Swine Fever Virus.

A Genetically Engineered Bivalent Vaccine Coexpressing a Molecular Adjuvant against Classical Swine Fever and Porcine Epidemic Diarrhea

Pigs Immunized with A Novel E2 Subunit Vaccine Are Protected from Subgenotype Heterologous Classical Swine Fever Virus Challenge